Stevens Capital Management’s Cytokinetics CYTK Stock Holding History

Stevens Capital Management’s Portfolio CYTK Stock Details CYTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q3	–	Sell	-40,924	Closed	-$495K	–	888
2017 Q2	$495K	Buy	+40,924	New	+$569K	0.02%	577
2016 Q1	–	Sell	-10,869	Closed	-$114K	–	932
2015 Q4	$114K	Buy	+10,869	New	+$107K	﹤0.01%	847
2015 Q3	–	Sell	-29,563	Closed	-$199K	–	1023
2015 Q2	$199K	Buy	29,563 +7,877	+36%	+$51.7K	0.01%	882
2015 Q1	$147K	Buy	+21,686	New	+$162K	0.01%	893
2014 Q2	–	Sell	-24,335	Closed	-$231K	–	1101
2014 Q1	$231K	Buy	+24,335	New	+$220K	0.01%	883

Other funds holding CYTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

LPU

Lansdowne Partners (UK) London, United Kingdom $1.87B AUM 61.55% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

Pinnacle Associates New York $7.78B AUM 45.07% 1-Year Est. Return

Stevens Capital Management's CYTK Position: Q3 2017 in Review

Stevens Capital Management sold out of Cytokinetics (CYTK) in Q3 2017, closing a stake of 40,924 shares — an estimated $495K sold.

Stevens Capital Management first reported a position in CYTK in Q1 2014 and held it in 5 quarters. The position peaked at $495K in Q2 2017. 132 funds tracked by Wall St. Rank hold CYTK as of Q3 2017.

Stevens Capital Management reported no remaining Cytokinetics position as of Q3 2017 after selling out during the quarter.
Stevens Capital Management sold 40,924 Cytokinetics shares in Q3 2017, an estimated $495K.
Stevens Capital Management first reported a position in Cytokinetics in Q1 2014 and held it in 5 quarters.
Stevens Capital Management's Cytokinetics position peaked at $495K in Q2 2017.
132 funds tracked by Wall St. Rank held Cytokinetics as of Q3 2017.

Based on Stevens Capital Management's 13F filing for Q3 2017, filed 1 Nov 2017.